Prostate Cancer Clinical Trial
Official title:
A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of FP253 in Combination With Fludarabine Phosphate
The primary objective of this study is to determine the safety and tolerability of a gene-directed enzyme prodrug therapy for prostate cancer. FP253 contains an ovine atadenovirus that expresses the E. coli enzyme purine nucleoside phosphorylase (PNP) under the control of a prostate-directed promoter. PNP converts systemically administered fludarabine (the prodrug) into 2-fluoroadenine (the active agent) at the site where FP253 has been administered (the prostate). This localized conversion is expected to provide organ-targeted chemotherapy that should reduce the systemic side effects associated with classical chemotherapy and also reduce the risk of debilitating damage to tissues surrounding the prostate.
OBJECTIVES: The primary objective of this study is to determine the safety and tolerability
of FP253 for prostate cancer. FP253 contains an ovine atadenovirus that expresses the E.
coli enzyme purine nucleoside phosphorylase (PNP) under the control of a prostate-directed
promoter.
SUBJECT POPULATION: Up to eighteen male subjects (6 groups of 3 subjects) who have a
histological diagnosis of adenocarcinoma of the prostate, still have their prostate in situ,
have evidence of progressive disease despite continuous androgen deprivation therapy and who
meet all eligibility criteria, will be enrolled into this study.
STUDY DESIGN: This study is designed as an open-label, dose escalation trial in which each
patient in a cohort will receive a single defined dose. Subjects will be enrolled
consecutively into 6 escalating dose groups each of 3 subjects. Each subject will receive
the treatment as outlined in the protocol and will be followed up for a further 2 years at
regular intervals for life, as defined by current standard of care.
TREATMENT: Subjects will be administered a single injection of FP253 followed by five doses
of Fludarabine phosphate as outlined in the Intervention section.
SAFETY PARAMETERS: Adverse events will be recorded and physical examinations, 12-lead ECG,
vital sign monitoring, urinalysis and collection of blood samples for pathology laboratory
tests will be performed at regular intervals during the study to monitor safety. The
shedding of viral vector will be monitored as per regulatory requirement until negative.
ADDITIONAL PARAMETERS: In order to assess any haematological or immunological effects of
this novel agent or any effects on tumour response and survival, the following will be
assessed:
- Biochemical and Haematological Markers: including Prostate-Specific Antigen,
- Immunopathological Markers: including haematological markers and indicators of
cytotoxicity,
- ECOG assessment,
- Assessment of disease progression and survival.
DATA ANALYSIS: Descriptive statistical methods will be used to summarize key data including
demographics, vital sign measurements, ECG parameters, clinical laboratory parameters,
immune response, tumour response, adverse events and concomitant medication. The general
strategy of the safety analysis will be to examine the data summaries for any trends in
safety parameters across the dose levels. No formal hypothesis will be tested.
A formal data analysis will be performed after all subjects have completed the study period
(28 days) and an interim analysis will be performed after the first 3 dose cohorts have been
completed. For the first year, three monthly follow up reports will be produced followed by
6 monthly reports for the second year and a final follow up report when all subjects have
completed 2 years of follow up. Descriptive statistical methods will be used to summarise
key data including demographics, vital sign measurements, ECG parameters, clinical
laboratory parameters, immune response, tumour response, adverse events and concomitant
medication. The general strategy of the safety analysis will be to examine the data
summaries for any trends in safety parameters across the dose levels. No formal hypothesis
will be tested.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |